We are supporting two important sessions and will be available to discuss LUCIDITY throughout the week.
Developing Topics #83153 - Oral Presentation: Significant dose-dependent reduction in neurofilament light chain concentration in plasma with oral tau aggregation inhibitor hydromethylthionine mesylate (data results from LUCIDITY Phase 3 clinical trial) - Presented by Professor Claude Wischik, Co-Founder, Chairman and Chief Executive, TauRx Pharmaceuticals Ltd on Sunday, 16 July: 8:00 – 8:45 am CEST, RAI Amsterdam Convention Centre, Hall 12.
Sponsored Symposium: Wake Up...it's time for a new AD healthcare system! Panel discussion moderated by Dr. Serge Gauthier, Monday, 17 July: 6:15 – 7:45 am CEST, Hotel Okura Amsterdam, Grand Ballroom (Breakfast will be served).
TauRx and GT Diagnostics will be at Exhibit Booth 205 and look forward to meeting with delegates over the course of the event.
If you are attending the event, please look out for our communications providing details of how to arrange an in-person or virtual meeting.
